RESUMEN
We conducted a retrospective observational study to demonstrate that switching to insulin degludec from other long-acting insulins reduces the risk of hypoglycaemia events and improves glycaemic control in patients with type 2 diabetes and stage 2-3B chronic kidney disease.
Asunto(s)
Glucemia/análisis , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Hipoglucemia/prevención & control , Insulina de Acción Prolongada/uso terapéutico , Insuficiencia Renal Crónica/tratamiento farmacológico , Anciano , Diabetes Mellitus Tipo 2/complicaciones , Femenino , Humanos , Hipoglucemia/inducido químicamente , Hipoglucemiantes/uso terapéutico , Masculino , Persona de Mediana Edad , Pronóstico , Insuficiencia Renal Crónica/complicaciones , Estudios Retrospectivos , Factores de RiesgoRESUMEN
OBJECTIVE: Dulaglutide is an agonist of "glucagon-like peptide type 1â³ receptors (arGLP1). The clinical efficacy of this molecule is based on reductions in glycosylated hemoglobin (HbA1c) and weight, data shown in the pivotal AWARD studies. METHODS: We propose a retrospective and multicenter study that allows evaluating the effectiveness of dulaglutide at 24â¯months after treatment began, under conditions of usual clinical practice, and comparing the results obtained with those that are reflected in the controlled trials. RESULTS: The results show a reduction in the HbA1c levels -1.4% at 6â¯M and this reduction were maintained throughout 12â¯M and 24â¯M (pâ¯<â¯0.001). Plasma glucose showed significant reductions around -30â¯mg / dL at 6â¯months (pâ¯<â¯0.001) that remained until the end of the follow-up at 12 and 24â¯M, respectively. The weight decreased significantly at 6â¯M (pâ¯<â¯0.001) but continued decreasing at 12 and 24â¯M, showing statistically significant differences (p: 0.001). CONCLUSIONS: Our results are similar to those obtained in pivotal clinical trials and confirm these benefits in real life.